Medelis Europe delivers complete oncology drug development services from preclinical through Phase III. The European, US and Asian sponsors looking to bring drugs to the US and European markets can utilize Medelis’s full service offering including electronic data capture for Phase I studies, internet-based patient recruitment, and integrated preclinical studies aligning the preclinical, regulatory and clinical teams, said Medelis.
Formerly of Tessman Technology and Ilex Pharmaceuticals, Dr Tessman brings more than 30 years of worldwide drug development and regulatory experience to the Medelis organization. She has directed all phases of pharmaceutical development from research through drug approval and marketing with additional expertise in the startup and turnaround of pharmaceutical companies.
Bob Bosserman, CEO of Medelis, said: “We are excited to take this significant step in expanding our geographical coverage and our service offerings to our worldwide clients who wish to bring their drugs to the European community for approval and sale.
“Dr Tessman has a long-term relationship with Medelis, and we’re delighted to make it official. Deirdre has an excellent track record and established reputation for founding and holding senior positions within both CROs and pharmaceutical companies. She is the clear choice to lead our firm’s European office and will be a substantial asset for our US and European clients as well as for Medelis’s continuing evolution as a worldwide leader in oncology drug development.”